Propanc Bio - PPCB STOCK NEWS

Propanc Biopharma (OTC Pink: PPCB) has received a Notice of Allowance for its 'Proenzyme Composition' patent from the Canadian Intellectual Property Office. This patent broadly covers high dose and high ratio claims for future clinical doses of PRP, the company's lead asset for treating recurring and metastatic cancer. It's the second Canadian patent allowed or granted, part of Propanc's 93-patent portfolio filed in major jurisdictions. The patent is important for future clinical dosage ranges as Propanc advances towards a Phase 1 First-In-Human study in advanced cancer patients with solid tumors. PRP targets the global metastatic cancer treatment market, projected to reach $111.2 Billion by 2027. The patent has been granted in Europe, Japan, and South East Asia, and is under examination in the US.

Propanc Biopharma (OTC Pink: PPCB) announces that its lead asset, PRP, could potentially solve the problem affecting response rates of immune checkpoint inhibitors in treating PD-L1-High solid tumors. Dr. Julian Kenyon, CSO, predicts that pretreatment with PRP could reverse the promotion of epithelial to mesenchymal transition (EMT) pathways induced by PD-L1, which are responsible for tumor growth and metastasis.

The Immune Checkpoint Inhibitors Market, valued at $47.22 Billion in 2023, is expected to reach $158.26 Billion by 2031. However, response rates for most solid tumors range only between 15-30%. A recent study in the British Journal of Cancer suggests that EMT induced by tumor cell-intrinsic PD-L1 signaling predicts poor response to immune checkpoint inhibitors in PD-L1-High lung cancer.

Dr. Kenyon believes PRP could enable PD-L1 non-responders to become responders by inducing cell differentiation in cancer cells, reversing EMT pathways, and reducing metastatic potential.

Propanc Biopharma, a biopharmaceutical company, announced receiving a Certificate of Grant for its “proenzymes composition” patent from the Japanese Patent Office, marking its fourth Japanese patent. This patent covers dosing regimen claims for PRP, the company's lead asset, advancing to clinical development. Additionally, the Intellectual Property of Malaysia granted a patent for a cancer treatment using trypsinogen and chymotrypsinogen, the company's third patent in Malaysia. Propanc's intellectual property portfolio now includes 93 patents worldwide for using PRP against solid tumors. Japan's pharmaceutical market, projected to reach $46.36 billion in 2024, is a key market for Propanc. The company aims to advance PRP into a Phase 1b clinical study, targeting and eradicating cancer stem cells without severe side effects.

Propanc Biopharma receives a certificate of grant for the 'Composition of Proenzymes for Cancer Treatment' patent from the European Patent Office. The patent covers lower dosage ratios of the two proenzymes in the PRP formulation, expanding the Company's IP portfolio to 94 patents filed globally. This development is important as the Company progresses into early-stage clinical trials, aiming to establish itself as a leader in cancer treatment innovation.

Propanc Biopharma, Inc. CEO, Mr. James Nathanielsz, discusses the competitive advantage of the company in revolutionizing cancer treatment on a podcast with Joel Block. Key points include global financing strategy, benefits of being a public company, ethical communication, patient-centric drug development, and science-based differentiation.

Propanc Biopharma, Inc. (PPCB) announces remarkable results from a compassionate use study on their proenzyme therapy for advanced metastatic cancers. The study showed a 41.3% survival rate longer than expected, with no severe adverse events. Management will discuss these results and plans for advancing their lead asset in a corporate update call on March 28, 2024.

Propanc Biopharma, Inc. (PPCB) announces the validation of PRP dosing and method to treat cancer stem cells patents in countries across Europe, resulting in a growing IP portfolio of 87 patents. The company has achieved grant status for the foundation patent in over 30 different countries across North America, Europe, Asia, the Middle East, and Japan. The PRP dosing patent covers possible future clinical dosage ranges for PRP as the company advances into early stage clinical development. The claims for the CSCs patent cover a method to minimize the progression of cancer in a patient who has already received a first-line treatment by detecting the presence of CSCs, followed by administering PRP. Europe is considered a major global region for pharmaceutical sales, and the company aims to establish itself as a pioneer in novel cancer treatments using proenzyme technology.

Propanc Biopharma, Inc. (PPCB) engages boutique advisory firm to identify strategic investment opportunities for advancing cancer treatment PRP and Rec-PRP. PRP shows promising effects against cancer stem cells, offering a less toxic alternative to standard treatments.

Propanc Biopharma, Inc. (OTC Pink: PPCB) is developing novel cancer treatments for recurring and metastatic cancer. The company's joint researcher has commenced an internship at the Cancer Center Amsterdam - vUMC. Preclinical research shows promising results for PRP, a mixture of two proenzymes, as a chemosensitizing agent for resistant tumors.